Ocugen (NASDAQ:OCGN - Get Free Report) had its target price boosted by research analysts at Chardan Capital from $4.00 to $5.00 in a note issued to investors on Monday, Benzinga reports. The firm currently has a "buy" rating on the stock. Chardan Capital's price objective would suggest a potential upside of 303.23% from the company's previous close.
Separately, HC Wainwright reiterated a "buy" rating and set a $7.00 target price on shares of Ocugen in a report on Wednesday, April 3rd.
Read Our Latest Report on Ocugen
Ocugen Trading Down 6.1 %
Shares of Ocugen stock traded down $0.08 during trading on Monday, reaching $1.24. 7,643,049 shares of the stock were exchanged, compared to its average volume of 8,121,908. The company has a quick ratio of 2.51, a current ratio of 2.51 and a debt-to-equity ratio of 0.07. The stock's fifty day moving average is $1.23 and its 200 day moving average is $0.73. The firm has a market cap of $319.09 million, a price-to-earnings ratio of -4.48 and a beta of 3.51. Ocugen has a 1 year low of $0.35 and a 1 year high of $2.11.
Institutional Trading of Ocugen
A hedge fund recently bought a new stake in Ocugen stock. David J Yvars Group acquired a new position in Ocugen, Inc. (NASDAQ:OCGN - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 21,170 shares of the company's stock, valued at approximately $35,000. Institutional investors and hedge funds own 10.27% of the company's stock.
About Ocugen
(
Get Free Report)
Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD.
Featured Articles
Before you consider Ocugen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocugen wasn't on the list.
While Ocugen currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
